Eicosanoid pathway in colorectal cancer: Recent updates


Tuncer S., BANERJEE S.

WORLD JOURNAL OF GASTROENTEROLOGY, cilt.21, sa.41, ss.11748-11766, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 41
  • Basım Tarihi: 2015
  • Doi Numarası: 10.3748/wjg.v21.i41.11748
  • Dergi Adı: WORLD JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.11748-11766
  • Anahtar Kelimeler: Eicosanoids, Cyclooxygenase, Lipoxygenase, Inflammation, Colorectal cancer, PROLIFERATOR-ACTIVATED-RECEPTOR, ENDOTHELIAL GROWTH-FACTOR, FACTOR-KAPPA-B, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, CYCLOOXYGENASE-2 GENE-EXPRESSION, POLYUNSATURATED FATTY-ACIDS, COLON-CANCER, PROSTAGLANDIN E-2, PPAR-GAMMA, CELL-PROLIFERATION
  • Orta Doğu Teknik Üniversitesi Adresli: Evet

Özet

Enzymatic metabolism of the 20C polyunsaturated fatty acid (PUFA) arachidonic acid (AA) occurs via the cyclooxygenase (COX) and lipoxygenase (LOX) pathways, and leads to the production of various bioactive lipids termed eicosanoids. These eicosanoids have a variety of functions, including stimulation of homeostatic responses in the cardiovascular system, induction and resolution of inflammation, and modulation of immune responses against diseases associated with chronic inflammation, such as cancer. Because chronic inflammation is essential for the development of colorectal cancer (CRC), it is not surprising that many eicosanoids are implicated in CRC. Oftentimes, these autacoids work in an antagonistic and highly temporal manner in inflammation; therefore, inhibition of the pro-inflammatory COX-2 or 5-LOX enzymes may subsequently inhibit the formation of their essential products, or shunt substrates from one pathway to another, leading to undesirable side-effects. A better understanding of these different enzymes and their products is essential not only for understanding the importance of eicosanoids, but also for designing more effective drugs that solely target the inflammatory molecules found in both chronic inflammation and cancer. In this review, we have evaluated the cancer promoting and anti-cancer roles of different eicosanoids in CRC, and highlighted the most recent literature which describes how those molecules affect not only tumor tissue, but also the tumor microenvironment. Additionally, we have attempted to delineate the roles that eicosanoids with opposing functions play in neoplastic transformation in CRC through their effects on proliferation, apoptosis, motility, metastasis, and angiogenesis.